AEON Biopharma, Inc. 8-K

What Happened AEON Biopharma, Inc. announced on May 14, 2026 (Form 8-K, Item 7.01) that it made a corporate presentation available in the investor relations section of its website. The presentation is furnished as Exhibit 99.1 to the 8-K and may be used by management in future meetings. The presentation includes a slide titled “Forward-Looking Statements” addressing risk and cautionary language. The filing is signed by CEO Robert Bancroft.

Key Details

• Date filed: May 14, 2026 (Form 8-K, Item 7.01 disclosure).
• Exhibit included: Exhibit 99.1 — Corporate Presentation dated May 2026.
• Disclosure type: Regulation FD (making corporate materials publicly available).
• Signature: Filed and signed by Robert Bancroft, Chief Executive Officer.

Why It Matters This 8-K does not report earnings, revenue, executive changes, or a transaction; it notifies investors that AEON has publicly posted updated corporate materials. Investors should review the presentation for any strategic updates, product or program highlights, and the company’s forward-looking statements, but note the filing itself is informational under Reg FD rather than a financial or operational disclosure.